ES2382457T3 - Materiales y procedimientos relacionados con la agregación de proteínas en enfermedades neurodegenerativas - Google Patents
Materiales y procedimientos relacionados con la agregación de proteínas en enfermedades neurodegenerativasInfo
- Publication number
- ES2382457T3 ES2382457T3 ES02734847T ES02734847T ES2382457T3 ES 2382457 T3 ES2382457 T3 ES 2382457T3 ES 02734847 T ES02734847 T ES 02734847T ES 02734847 T ES02734847 T ES 02734847T ES 2382457 T3 ES2382457 T3 ES 2382457T3
- Authority
- ES
- Spain
- Prior art keywords
- tau
- aggregation
- pea
- protein
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0100119 | 2001-01-03 | ||
| GBGB0100119.7A GB0100119D0 (en) | 2001-01-03 | 2001-01-03 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| PCT/GB2002/000005 WO2002059150A2 (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2382457T3 true ES2382457T3 (es) | 2012-06-08 |
Family
ID=9906201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02734847T Expired - Lifetime ES2382457T3 (es) | 2001-01-03 | 2002-01-02 | Materiales y procedimientos relacionados con la agregación de proteínas en enfermedades neurodegenerativas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7834237B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1348029B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4580618B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE548453T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002217310B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2433535C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1348029T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2382457T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0100119D0 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1348029E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002059150A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0104685D0 (en) * | 2001-02-26 | 2001-04-11 | Leuven K U Res & Dev | Tau-opathy model |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| WO2004007722A2 (en) * | 2002-07-12 | 2004-01-22 | Axon Neuroscience Forschungs- Und Entwicklungs Gmbh | Transgenic animal expressing alzheimer’s tau protein |
| EP1516930A1 (en) * | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Cellular model of tauopathies for lead identification and drug discovery |
| DE602005016537D1 (de) * | 2004-03-31 | 2009-10-22 | Anges Mg Inc | Testverfahren zur identifizierung eines kandidatenarzneistoffs |
| ES2770067T3 (es) | 2004-05-11 | 2020-06-30 | Ncardia Ag | Descubrimiento de fármacos basado en células diferenciadas in vitro |
| JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| WO2007066809A1 (ja) * | 2005-12-06 | 2007-06-14 | Tokyo Metropolitan Organization For Medical Research | タンパク質重合体の重合核となりうるタンパク質又はその重合体が導入された細胞及びその製造法 |
| DK2004155T3 (en) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| PT2954932T (pt) | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| WO2012106363A2 (en) | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| WO2012162179A1 (en) | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| CN111094327A (zh) * | 2017-08-16 | 2020-05-01 | Lgv1有限公司 | Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型 |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CN113943766B (zh) * | 2021-11-26 | 2024-01-26 | 守正创新生物科技(天津)有限公司 | 一种抗糖化寡肽-5(AdP)的制备及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE569430A (cg-RX-API-DMAC7.html) | 1957-07-17 | |||
| GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
| US5571666A (en) | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| US5912410A (en) | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| CA2110488A1 (en) | 1991-07-10 | 1993-01-21 | Franceska Fieuws | Fluorochemical water- and oil-repellent treating compositions |
| WO1993003369A1 (en) | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| GB9316727D0 (en) | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
| FR2722695B1 (fr) | 1994-07-22 | 1997-04-25 | Demic Lab Sa | Ustensile de badigeonnage cutane par frottement a usage medical |
| WO1996004915A1 (en) | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| US5898094A (en) | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| WO1999062548A1 (en) | 1998-06-01 | 1999-12-09 | Advanced Research And Technology Institute | Methods and compositions for diagnosing tauopathies |
| DE19920514A1 (de) * | 1999-05-05 | 2000-11-16 | Boehringer Ingelheim Pharma | Methoden zur Auffindung von Proteasen, die spezifisch membrangebundene Substrate spalten |
| WO2001053340A2 (en) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| JP2001352860A (ja) * | 2000-06-15 | 2001-12-25 | Inst Of Physical & Chemical Res | 老年期痴呆症で生じる神経原線維変化を示すマウス |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US20030217370A1 (en) | 2002-05-16 | 2003-11-20 | Giasson Benoit I. | Transgenic animal expressing alpha-synuclein and uses thereof |
| US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
-
2001
- 2001-01-03 GB GBGB0100119.7A patent/GB0100119D0/en not_active Ceased
-
2002
- 2002-01-02 EP EP02734847A patent/EP1348029B1/en not_active Expired - Lifetime
- 2002-01-02 WO PCT/GB2002/000005 patent/WO2002059150A2/en not_active Ceased
- 2002-01-02 PT PT02734847T patent/PT1348029E/pt unknown
- 2002-01-02 US US10/451,367 patent/US7834237B2/en not_active Expired - Lifetime
- 2002-01-02 DK DK02734847.3T patent/DK1348029T3/da active
- 2002-01-02 ES ES02734847T patent/ES2382457T3/es not_active Expired - Lifetime
- 2002-01-02 CA CA2433535A patent/CA2433535C/en not_active Expired - Lifetime
- 2002-01-02 JP JP2002559452A patent/JP4580618B2/ja not_active Expired - Lifetime
- 2002-01-02 AT AT02734847T patent/ATE548453T1/de active
- 2002-01-02 AU AU2002217310A patent/AU2002217310B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002217310B2 (en) | 2007-09-20 |
| JP2004531224A (ja) | 2004-10-14 |
| WO2002059150A2 (en) | 2002-08-01 |
| PT1348029E (pt) | 2012-06-15 |
| DK1348029T3 (da) | 2012-05-29 |
| CA2433535A1 (en) | 2002-08-01 |
| CA2433535C (en) | 2011-02-15 |
| EP1348029B1 (en) | 2012-03-07 |
| HK1056574A1 (en) | 2004-02-20 |
| GB0100119D0 (en) | 2001-02-14 |
| US20040078835A1 (en) | 2004-04-22 |
| JP4580618B2 (ja) | 2010-11-17 |
| WO2002059150A3 (en) | 2002-12-05 |
| EP1348029A2 (en) | 2003-10-01 |
| US7834237B2 (en) | 2010-11-16 |
| ATE548453T1 (de) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7834237B2 (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| ES2407204T3 (es) | Materiales y procedimientos relacionados con la agregación de proteínas en la enfermedad neurodegenerativa | |
| AU2002217310A1 (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| Melis et al. | Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration | |
| Lazarov et al. | Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited | |
| Hansen et al. | A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP | |
| JP4414332B2 (ja) | アルツハイマーtauタンパク質を発現するトランスジェニック動物 | |
| Wang et al. | Isoform‐specific knockout of FE65 leads to impaired learning and memory | |
| AU2002225147A1 (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| Mi et al. | Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice | |
| US9265788B2 (en) | Compositions and methods for treatment of mitochondrial diseases | |
| ES2295949T3 (es) | Tratamiento de enfermedades neurodegenerativas mediante el uso de inhibidores de degs. | |
| US20090010894A1 (en) | Methods and systems for identifying compounds that modulate alpha-synuclein aggregation | |
| JP2020524132A (ja) | アルツハイマー病を治療するための組成物および方法 | |
| HK1056574B (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| US20190263867A1 (en) | Tau peptides, methods of making, and methods of using | |
| NO334611B1 (no) | Transgent ikke-humant dyr med en nukleinsyresekvens som koder for presenilin 1 protein, celle eller cellelinje avledet fra dyret, mutert muse PS1- protein, nukleinsyre som koder for proteinet, vektor omfattende nukleinsyren, anvendelse av det transgene dyret for å påvise forbindelser til behandling av Alzheimers sykdom samt fremgangsmåte for å påvise forbindelsene | |
| da Eira | New Insights on the Impact of Transthyretin in Neuroprotection and Neurodegeneration | |
| US20040048237A1 (en) | Mammalian prion proteins and transgenic mice expressing them | |
| CN118786138A (zh) | 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用 | |
| AU2007200212B2 (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| Fernandez | Palmitoylation mediates neuron-specific BACE1 localization: Implications for APP processing using a knock-in mouse model | |
| HK1055605B (en) | Materials and methods relating to protein aggregation in neurodegenerative disease |